Hospital
Pomerene Hospital
Pomerene Hospital was paid $4.66M by Medicaid between Jan 2018 and Dec 2024, across 105 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoPOMERENE HOSPITAL
MILLERSBURG, OH 44654
MILLERSBURG, OH 44654
33aNPI1770957185assigned 11/23/2015
33bProvider typeRural Acute Care Hospital
28Total paid$4.66M
24GClaims144,604
24DCodes billed105
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,960 | $430K | |
| 2019 | 12,367 | $364K | |
| 2020 | 10,078 | $386K | |
| 2021 | 12,836 | $530K | |
| 2022 | 15,011 | $477K | |
| 2023 | 52,003 | $1.63M | |
| 2024incomplete | 27,349 | $843K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 17,538 | 14,339 | $1.02M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 9,749 | 8,332 | $1.01M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 1,534 | 1,094 | $470K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.7% | 3,890 | 3,063 | $451K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.9% | 988 | 670 | $273K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 678 | 529 | $169K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.9% | 1,084 | 1,039 | $137K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.7% | 676 | 586 | $126K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 689 | 416 | $121K |
| 80053 | Comprehensive metabolic panel | 2.5% | 11,156 | 8,925 | $116K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 1,266 | 330 | $98K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 2,126 | 1,908 | $71K |
93 more codes
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.4% | 39 | $63K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.3% | 380 | $62K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 13,559 | $52K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 603 | $49K |
| 80061 | Lipid panel | 1.0% | 1,979 | $47K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 162 | $32K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 128 | $29K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,346 | $29K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,484 | $27K |
| G0378 | Hospital observation service, per hour | <1% | 406 | $23K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,312 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,429 | $17K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 153 | $17K |
| 84439 | <1% | 699 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 604 | $14K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 238 | $12K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 881 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,347 | $8K |
| 87088 | <1% | 783 | $8K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 28 | $6K |
| 86140 | <1% | 1,310 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 238 | $6K |
| 81001 | <1% | 4,539 | $3K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 266 | $3K |
| 84484 | <1% | 2,348 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,399 | $3K |
| 0002A | <1% | 86 | $3K | |
| 85027 | <1% | 324 | $3K | |
| 0001A | <1% | 78 | $2K | |
| 83880 | <1% | 663 | $2K | |
| 87400 | <1% | 100 | $2K | |
| 85610 | <1% | 390 | $2K | |
| 82607 | <1% | 112 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 722 | $2K |
| 83735 | <1% | 326 | $2K | |
| 83690 | <1% | 1,471 | $1K | |
| 83605 | <1% | 826 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 118 | $1K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,178 | $1K |
| 82570 | <1% | 115 | $927.27 | |
| 84703 | <1% | 1,058 | $908.55 | |
| 80164 | <1% | 56 | $828.34 | |
| 85379 | <1% | 539 | $750.35 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,441 | $741.05 |
| 00160 | <1% | 34 | $708.74 | |
| 87040 | <1% | 751 | $689.52 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,364 | $567.78 |
| 82948 | <1% | 433 | $484.12 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,760 | $470.35 |
| 87070 | <1% | 62 | $407.63 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,090 | $379.56 |
| 80076 | <1% | 58 | $317.36 | |
| 82043 | <1% | 43 | $298.78 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 688 | $297.07 |
| 96376 | <1% | 448 | $284.30 | |
| 85651 | <1% | 61 | $262.94 | |
| 82728 | <1% | 14 | $262.25 | |
| 83540 | <1% | 27 | $255.82 | |
| 84702 | <1% | 18 | $242.70 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,753 | $239.67 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 55 | $213.27 |
| 87807 | <1% | 208 | $200.64 | |
| 82746 | <1% | 13 | $162.83 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,457 | $126.48 |
| 87430 | <1% | 153 | $120.77 | |
| 73110 | <1% | 17 | $109.58 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,651 | $107.93 |
| 87486 | <1% | 40 | $106.62 | |
| 87581 | <1% | 40 | $106.62 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 638 | $105.21 |
| 85730 | <1% | 43 | $100.43 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 456 | $98.93 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 79 | $93.07 |
| 87081 | <1% | 44 | $68.54 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 25 | $55.48 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,990 | $46.19 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,192 | $37.22 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 808 | $21.10 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 44 | $20.86 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 47 | $11.31 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 559 | $10.94 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 82 | $5.85 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,207 | $3.56 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 58 | $2.19 |
| 91300 | <1% | 167 | $1.37 | |
| J2704 | Injection, propofol, 10 mg | <1% | 956 | $0.19 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 127 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 41 | $0.00 |
| G8598 | Aspirin or another antiplatelet therapy used | 0% | 33 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 13 | $0.00 |
| 73610 | 0% | 16 | $0.00 | |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 73 | $0.00 |
| 80320 | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCERNAVA, TIA (CFO)